Compare · ABBV vs SIGA
ABBV vs SIGA
Side-by-side comparison of AbbVie Inc. (ABBV) and SIGA Technologies Inc. (SIGA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and SIGA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $402.35B, about 1298.5x SIGA ($309.8M).
- Over the past year, ABBV is up 19.3% and SIGA is down 33.6% - ABBV leads by 52.9 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- ABBV has more recent analyst coverage (25 ratings vs 0 for SIGA).
- Company
- AbbVie Inc.
- SIGA Technologies Inc.
- Price
- $227.67+1.37%
- $4.32+0.35%
- Market cap
- $402.35B
- $309.8M
- 1M return
- +9.19%
- +0.23%
- 1Y return
- +19.28%
- -33.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
SIGA Technologies Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was founded in 1995 and is headquartered in New York, New York.
Latest ABBV
- Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Latest SIGA
- Director Marshall Joseph W Iii converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 7% to 246,523 units (SEC Form 4) (withholding tax)
- Director Keane John M converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39) (SEC Form 4) to satisfy withholding obligation
- Director Ford Harold Eugene Jr. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 55% to 47,538 units (SEC Form 4) (withholding obligation)
- Director Phillips Holly L. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to cover withholding tax
- Director Nemirovsky Julian converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to satisfy withholding obligation
- Director Durnan Jaymie A converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 23% to 88,754 units (SEC Form 4) (tax liability)
- Director Nabel Gary J. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) (for tax liability)
- SIGA Technologies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by SIGA Technologies Inc.
- SEC Form 10-Q filed by SIGA Technologies Inc.